Fig. 7From: Identification and validation of an individualized metabolic prognostic signature for predicting the biochemical recurrence of prostate cancer based on the immune microenvironmentThe grouping ability of the MTGs-based signature determined by PCA. A PCA based on the training set gene expression profile. B PCA based on the test set gene expression profile. C PCA based on all the MTGs. D PCA based on the risk signatureBack to article page